Walvax Shipped the First Batch of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine to the Kingdom of Morocco
May 21, 2022, Kunming — Walvax Biotechnology Co., Ltd. ("Walvax", together with its subsidiaries, the "Group", stock code: 300142.SZ) is pleased to announce that the Group’s subsidiary, Yuxi Walvax Biotechnology Co., Ltd., has produced and shipped the first batch of one million doses of its 13-valent pneumococcal polysaccharide conjugate vaccine ("PCV13") to the Kingdom of Morocco. A ceremony of the shipping was held in Yuxi Municipality, Yunnan, China on the morning of Saturday, May 21st, 2022, with the attendance of government officials at both provincial and municipal level.
On January 29th, 2022, Morocco and Walvax entered into a commitment to supply 2 million doses of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in the format of finished product and bulk drug substance. In the same month, the Ministry of Health of Morocco granted the market authorization to Walvax's PCV13 product.
Walvax's PCV13 product, the second approved 13-valent pneumococcal polysaccharide conjugate vaccine in the world, is indicated for the prevention of invasive diseases caused by 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) of S. pneumoniae, in infants and children aged 6 weeks through 5 years. Its clinical studies have demonstrated its safety and immunogenicity comparable to the reference vaccine. This PCV13 will support Morocco’s immunization programs and will further enhance the health of millions of people in the Kingdom.
The Board of Walvax Biotechnology Co., Ltd., commented: "It is a significant milestone in the cooperation between Walvax and Morocco, and a good signal for the long-term partnership to forge ahead. PCV13 is included in the Expanded Programme on Immunization in the Kingdom of Morocco, to protect millions of children from life-threatening disease. We are delighted to make a big step to deliver on our promise to the world, that is, 'Help everyone live a healthy life', through supplying those in need with safe and efficacious vaccines of high quality, at an affordable price and in a sustainable manner.”
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious vaccines. Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines since then. As of May 2022, Walvax has successfully developed 8 licensed vaccines (12 presentations), including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV-2). For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.